Publications by authors named "I Quintus Molenaar"
Introduction: Adjuvant chemotherapy improves survival in patients with resected pancreatic ductal adenocarcinoma (PDAC). The decision to initiate chemotherapy involves both patient and physician factors, decision-specific criteria, and contextual considerations. This study aimed to assess medical oncologists' views on adjuvant chemotherapy following pancreatic resection for PDAC.
View Article and Find Full Text PDFDefining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An International Multicenter Study.
Ann Surg Oncol
December 2024
Article Synopsis
- This study investigates early recurrence in patients with pancreatic ductal adenocarcinoma (PDAC) derived from intraductal papillary mucinous neoplasm (IPMN), aiming to identify predictors to help guide patient management.
- The research found that early recurrence is defined as occurring within 10.5 months post-surgery, affecting 38% of patients who experienced recurrence, with CA19-9 levels and N2 disease being significant predictors.
- Adjuvant chemotherapy showed a survival advantage only for high-risk patients, highlighting the importance of risk stratification for better treatment outcomes.
Importance: Postoperative pancreatic fistulas (POPF) are the biggest contributor to surgical morbidity and mortality after pancreatoduodenectomy. The impact of POPF could be influenced by the surgical approach.
Objective: To assess the clinical impact of POPF in patients undergoing minimally invasive pancreatoduodenectomy (MIPD) and open pancreatoduodenectomy (OPD).
Article Synopsis
- - The study examined survival scenarios for pancreatic adenocarcinoma (PAC) patients over 16 years, highlighting best-case, typical, and worst-case survival estimates based on data from the Netherlands Cancer Registry.
- - Patients with localized PAC showed statistically significant improvements in best-case and typical survival scenarios, with gains averaging 1.54 and 0.24 months annually, respectively, while those with metastatic PAC experienced smaller but significant improvements.
- - Factors like age, aggressive treatments, and fewer comorbidities were linked to better survival outcomes, suggesting that recent advancements in care may offer hopeful prospects for PAC patients, despite small absolute survival gains.
Article Synopsis
- Patients with colorectal cancer and liver-only metastases showed improved outcomes when treated with FOLFOXIRI and bevacizumab compared to FOLFIRI and bevacizumab or with panitumumab, especially regarding progression-free survival and resection rates.
- The CAIRO5 trial involved 530 patients with initially unresectable liver metastases from colorectal cancer, evaluated across numerous centers in the Netherlands and Belgium, focusing on different treatment combinations based on tumor genetics.
- While more effective responses were observed with certain treatments, there was an increase in toxic side effects, particularly in specific genetic tumor variants like RAS/BRAFV600E.